PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? (original) (raw)

• Issemann I, Green S . Activation of a member of the steroid-hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–650.
  CAS PubMed Google Scholar
• Knopp RH . Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498–511.
  CAS PubMed Google Scholar
• Hansen JB et al. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem 2001; 276: 3175–3182.
  CAS PubMed Google Scholar
• Peters JM et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20: 5119–5128.
  CAS PubMed PubMed Central Google Scholar
• Bastie C, Luquet S, Holst D, Jehl-Pietri C, Grimaldi PA . Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation. J Biol Chem 2000; 275: 38768–38773.
  CAS PubMed Google Scholar
• Leibowitz MD et al. Activation of PPAR delta alters lipid metabolism in db/db mice. FEBS Lett 2000; 473: 333–336.
  CAS PubMed Google Scholar
• Oliver Jr WR et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306–5311.
  CAS PubMed Google Scholar
• Ren DL, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS . PPAR gamma knockdown by engineered transcription factors: exogenous PPAR gamma 2 but not PPAR gamma 1 reactivates adipogenesis. Genes Develop 2002; 16: 27–32.
  CAS PubMed Google Scholar
• VidalPuig A et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996; 97: 2553–2561.
  CAS Google Scholar
• VidalPuig AJ et al. Peroxisome proliferator-activated receptor gene expression in human tissues—effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416–2422.
  CAS Google Scholar
• Auboeuf D et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans—no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319–1327.
  CAS PubMed Google Scholar
• Mukherjee R, Jow L, Croston GE, Paterniti JR . Identification characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR gamma 2 versus PPAR gamma 1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 8071–8076.
  CAS PubMed Google Scholar
• Kruszynska YT et al. Skeletal muscle peroxisome proli-ferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 1998; 101: 543–548.
  CAS PubMed PubMed Central Google Scholar
• Loviscach M et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 2000; 43: 304–311.
  CAS PubMed Google Scholar
• Forman BM et al. 15-Deoxy-delta(12,14)-prostaglandin J(2) is a ligand for the adipocyte determination factor ppar-gamma. Cell 1995; 83: 803–812.
  CAS PubMed Google Scholar
• Kliewer SA et al. A prostaglandin J(2) metabolite binds peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Cell 1995; 83: 813–819.
  CAS PubMed Google Scholar
• Kliewer SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318–4323.
  CAS PubMed Google Scholar
• Nagy L, Tontonoz P, Alvarez JGA, Chen HW, Evans RM . Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell 1998; 93: 229–240.
  CAS PubMed Google Scholar
• Desvergne B, Wahli W . Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–688.
  CAS PubMed Google Scholar
• Willson TM, Lambert MH, Kliewer SA . Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341–367.
  CAS PubMed Google Scholar
• Ibrahimi A et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 1994; 46: 1070–1076.
  CAS PubMed Google Scholar
• Oberfield JL et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102–6106.
  CAS PubMed Google Scholar
• Wright HM et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000; 275: 1873–1877.
  CAS PubMed Google Scholar
• Camp HS, Chaudhry A, Leff T . A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 2001; 142: 3207–3213.
  CAS PubMed Google Scholar
• Mukherjee R et al. A selective peroxisome proliferator-activated receptor-gamma (PPAR gamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocr 2000; 14: 1425–1433.
  CAS Google Scholar
• Morrison RF, Farmer SR . Role of PPAR gamma in regulating a cascade expression of cyclin-dependent kinase inhibitors p18(INK4c), and p21(Waf1/Cip1), during adipogenesis. J Biol Chem 1999; 274: 17088–17097.
  CAS PubMed Google Scholar
• Morrison RF, Farmer SR . Hormonal signaling and transcriptional control of adipocyte differentiation. J Nutr 2000; 130: 3116S–3121S.
  CAS PubMed Google Scholar
• Kim JB, Wright HM, Wright M, Spiegelman BM . ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA 1998; 95: 4333–4337.
  CAS PubMed Google Scholar
• Soukas A, Socci ND, Saatkamp BD, Novelli S, Friedman JM . Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem 2001; 276: 34167–34174.
  CAS PubMed Google Scholar
• Takamura T, Nohara E, Nagai Y, Kobayashi K . Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPAR gamma mRNA expression in 3T3-L1 adipocytes. Eur J Pharmacol 2001; 422: 23–29.
  CAS PubMed Google Scholar
• Vernochet C et al. PPARgamma-dependent and PPARgamma-independent effects on the development of adipose cells from embryonic stem cells. FEBS Lett 2002; 510: 94–98.
  CAS PubMed Google Scholar
• Tontonoz P, Hu E, Spiegelman BM . Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147–1156.
  CAS PubMed Google Scholar
• Hu E, Tontonoz P, Spiegelman BM . Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Proc Natl Acad Sci USA 1995; 92: 9856–9860.
  CAS PubMed Google Scholar
• Kubota N et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597–609.
  CAS PubMed Google Scholar
• Barak Y et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585–595.
  CAS PubMed Google Scholar
• Rosen ED et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611–617.
  CAS PubMed Google Scholar
• Gurnell M et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 2000; 275: 5754–5759.
  CAS PubMed Google Scholar
• Young PW et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751–759.
  CAS PubMed Google Scholar
• Werman A et al. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem 1997; 272: 20230–20235.
  CAS PubMed Google Scholar
• Hu E, Kim JB, Sarraf P, Spiegelman BM . Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996; 274: 2100–2103.
  CAS PubMed Google Scholar
• Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK . Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997; 272: 5128–5132.
  CAS PubMed Google Scholar
• Camp HS, Tafuri SR . Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 1997; 272: 10811–10816.
  CAS PubMed Google Scholar
• Yang W et al. Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem 2001; 276: 38341–38344.
  CAS PubMed Google Scholar
• Camp HS, Whitton AL, Tafuri SR . PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes. FEBS Lett 1999; 447: 186–190.
  CAS PubMed Google Scholar
• Hauser S et al. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000; 275: 18527–18533.
  CAS PubMed Google Scholar
• Lefebvre AM et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47: 98–103.
  CAS Google Scholar
• Hotta K et al. Relationships of PPARgamma and PPARgamma2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys. Int J Obes Relat Metab Disord 1998; 22: 1000–1010.
  CAS PubMed Google Scholar
• Edvardsson U et al. Rosiglitazone (BRL49653) a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res 1999; 40: 1177–1184.
  CAS PubMed Google Scholar
• Memon RA et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000; 141: 4021–4031.
  CAS PubMed Google Scholar
• Park KS et al. PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 1997; 46: 1230–1234.
  CAS PubMed Google Scholar
• Rieusset J et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes 1999; 48: 699–705.
  CAS PubMed Google Scholar
• Lapsys NM et al. Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. J Clin Endocrinol Metab 2000; 85: 4293–4297.
  CAS PubMed Google Scholar
• Rousseau V et al. Developmental and nutritional changes of ob and PPAR gamma 2 gene expression in rat white adipose tissue. Biochem J 1997; 321(Pt 2): 451–456.
  CAS PubMed PubMed Central Google Scholar
• Ribot J, Rantala M, Kesaniemi YA, Palou A, Savolainen MJ . Weight loss reduces expression of SREBP1c/ADD1 and PPARgamma2 in adipose tissue of obese women. Pflugers Arch 2001; 441: 498–505.
  CAS PubMed Google Scholar
• Nisoli E et al. Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes 2000; 49: 319–324.
  CAS PubMed Google Scholar
• Zierath JR et al. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998; 139: 5034–5041.
  CAS PubMed Google Scholar
• Hallakou S, Foufelle F, Doare L, Kergoat M, Ferre P . Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia 1998; 41: 963–968.
  CAS PubMed Google Scholar
• Way JM et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142: 1269–1277.
  CAS PubMed Google Scholar
• Jiang G et al. Potentiation of insulin signaling in tissues of zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 2002; 51: 2412–2419.
  CAS PubMed Google Scholar
• Boden G . Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3–10.
  CAS Google Scholar
• Yakubu-Madus FE, Stephens TW, Johnson WT . Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes Obes Metab 2000; 2: 155–163.
  CAS PubMed Google Scholar
• de Souza CJ et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863–1871.
  CAS PubMed Google Scholar
• Chao L et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidaemic, effect of thiazolidinediones. J Clin Invest 2000; 106: 1221–1228.
  CAS PubMed PubMed Central Google Scholar
• Yamauchi T et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276: 41245–41254.
  CAS PubMed Google Scholar
• Pickavance LC, Buckingham RE, Wilding JP . Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes Obes Metab 2001; 3: 171–180.
  CAS PubMed Google Scholar
• Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JP . Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 1999; 128: 1570–1576.
  CAS PubMed PubMed Central Google Scholar
• Danforth Jr E . Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 2000; 26: 13.
  CAS PubMed Google Scholar
• Arioglu E et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263–274.
  CAS PubMed Google Scholar
• Burant CF et al. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100: 2900–2908.
  CAS PubMed PubMed Central Google Scholar
• Hallakou S et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393–1399.
  CAS PubMed Google Scholar
• Okuno A et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354–1361.
  CAS PubMed PubMed Central Google Scholar
• Miles PD, Barak Y, He W, Evans RM, Olefsky JM . Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105: 287–292.
  CAS PubMed PubMed Central Google Scholar
• Deeb SS et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284–287.
  CAS Google Scholar
• Masugi J, Tamori Y, Mori H, Koike T, Kasuga M . Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268: 178–182.
  CAS PubMed Google Scholar
• Hara K et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun. 2000; 271: 212–216.
  CAS PubMed Google Scholar
• Altshuler D et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76–80.
  CAS PubMed Google Scholar
• Ek J et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 2001; 44: 1170–1176.
  CAS PubMed Google Scholar
• Ek J et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42: 892–895.
  CAS Google Scholar
• Beamer BA et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47: 1806–1808.
  CAS Google Scholar
• Barroso I et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–883.
  CAS PubMed Google Scholar
• Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR . Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953–959.
  CAS Google Scholar
• Schmitz OE, Brock B, Madsbad S, Beck-Nielsen H . [Thiazolidinediones--a new class of oral antidiabetics]. Ugeskr Laeger 2001; 163: 6106–6111.
  CAS PubMed Google Scholar
• Zinman B . PPAR gamma agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab 2001; 3 (Suppl 1): S34–S43.
  CAS PubMed Google Scholar
• Unger RH, Orci L . Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001; 15: 312–321.
  CAS PubMed Google Scholar
• Bedoucha M, Atzpodien E, Boelsterli UA . Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001; 35: 17–23.
  CAS PubMed Google Scholar
• Camp HS et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000; 49: 539–547.
  CAS PubMed Google Scholar
• Malinowski JM, Bolesta S . Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22: 1151–1168.
  CAS PubMed Google Scholar
• Miyazaki Y, Matsuda M, DeFronzo RA . Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517–523.
  CAS PubMed Google Scholar
• Belcher G, Matthews DR . Safety and tolerability of pioglitazone. Exper Clin Endocr Diabetes 2000; 108: S267–S273.
  Google Scholar
• Shimizu H et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470–1474.
  CAS PubMed Google Scholar
• Schwartz MW, Boyko EJ, Kahn SE, Ravussin E, Bogardus C . Reduced insulin secretion: an independent predictor of body weight gain. J Clin Endocrinol Metab 1995; 80: 1571–1576.
  CAS PubMed Google Scholar
• Kelly IE, Han TS, Walsh K, Lean ME . Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288–293.
  CAS PubMed Google Scholar
• Mori Y et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22: 908–912.
  CAS PubMed Google Scholar
• Kawai T et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 1999; 48: 1102–1107.
  CAS PubMed Google Scholar
• Miyazaki Y et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Diabetes 2000; 49 (Suppl 1): A299 (Ref Type: Abstract).
  Google Scholar
• Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K . Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23, 1067–1071.
  CAS PubMed Google Scholar
• Nakamura T et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation—double-blind placebo-controlled trial. Diabetes Res Clin Pract 2001; 54: 181–190.
  CAS PubMed Google Scholar
• Montague CT, O'Rahilly S . The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49: 883–888.
  CAS Google Scholar
• Yanase T et al. Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue. Biochem Biophys Res Commun 1997; 233: 320–324.
  CAS PubMed Google Scholar
• Adams M et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149–3153.
  CAS PubMed PubMed Central Google Scholar
• Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S . Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 2002; 51: 718–723.
  CAS PubMed Google Scholar
• Hauner H, Wabitsch M, Pfeiffer EF . Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. Horm Metab Res Suppl 1988; 19: 35–39.
  CAS PubMed Google Scholar
• Miyazaki Y et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44: 2210–2219.
  CAS PubMed Google Scholar
• Iwamoto Y et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151–156.
  CAS PubMed Google Scholar
• Chilcott J, Tappenden P, Llyod Jones M, Wight JP . A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001; 23: 1792–1823.
  CAS PubMed Google Scholar
• Frias JP, Yu JG, Kruszynska YT, Olefsky JM . Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 2000; 23: 64–69.
  CAS PubMed Google Scholar
• Rocchi S et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8: 737–747.
  CAS PubMed Google Scholar
• Shimaya A et al. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism 2000; 49: 411–417.
  CAS PubMed Google Scholar